Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 5.71
+0.16 (2.88%)
Sep 30, 2026, 4:08 PM HKT
Sino Biopharmaceutical Stock Forecast
Stock Price Forecast
According to 24 analysts polled by S&P Global, Sino Biopharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $8.45. The average 1-year stock price forecast is 47.99% higher than the current stock price, while the lowest is $5.92 (+3.68%) and the highest is $10.93 (+91.42%).
Price Target: $8.45 (+47.99%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Sino Biopharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 16 | 17 | 17 |
| Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 22 | 22 | 22 | 24 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Guosheng Securities No rating | Guosheng Securities | Buy Maintains $8.20 | Buy | Maintains | $8.20 | +43.61% | Sep 4, 2026 |
Unknown Analyst Shenwan Hongyuan No rating | Shenwan Hongyuan | Buy Maintains $10.40 | Buy | Maintains | $10.40 | +82.14% | Aug 27, 2026 |
Unknown Analyst China Merchants Securities No rating | China Merchants Securities | Buy Maintains $9.80 | Buy | Maintains | $9.80 | +71.63% | Aug 25, 2026 |
Unknown Analyst BOCOM International Holdings Company No rating | BOCOM International Holdings Company | Buy Maintains $7.70 → $10.00 | Buy | Maintains | $7.70 → $10.00 | +75.13% | Aug 22, 2026 |
Unknown Analyst CMB International Securities No rating | CMB International Securities | Buy Maintains $8.70 | Buy | Maintains | $8.70 | +52.36% | Aug 22, 2026 |
Financial Forecast
Revenue This Year
36.37B
from 31.83B
Increased by 14.25%
Revenue Next Year
38.60B
from 36.37B
Increased by 6.12%
EPS This Year
0.26
from 0.25
Increased by 3.45%
EPS Next Year
0.27
from 0.26
Increased by 2.31%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.